TY - JOUR
KW - Analgesics, Opioid/therapeutic use
KW - Cohort Studies
KW - Female
KW - Humans
KW - Medicaid
KW - Opioid-Related Disorders/drug therapy/epidemiology
KW - Pregnancy
KW - prescriptions
KW - Prevalence
KW - United States/epidemiology
KW - United States
KW - Opioids
KW - Trends
AU - G. Pocobelli
AU - S. Dublin
AU - J. F. Bobb
AU - L. Albertson-Junkans
AU - S. Andrade
AU - T. C. Cheetham
AU - G. Salgado
AU - M. R. Griffin
AU - M. A. Raebel
AU - D. Smith
AU - D. K. Li
AU - P. A. Pawloski
AU - S. Toh
AU - L. Taylor
AU - W. Hua
AU - P. Horn
AU - J. P. Trinidad
AU - D. M. Boudreau
A1 - 
AD - Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.; Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.; Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.; Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.; Meyers Primary Care Institute, Worcester, Massachusetts, USA.; Kaiser Permanente Southern California, Department of Research & Evaluation, Pasadena, CA, Chapman University, School of Pharmacy, Irvine, CA, USA.; Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.; Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Institute for Health Research, Kaiser Permanente Colorado, Colorado, USA.; Kaiser Permanente Center for Health Research, Portland, Oregon, USA.; Kaiser Foundation Research Institute, Oakland, California, USA.; Health Partners Institute, Bloomington, Minnesota, USA.; Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.; Food and Drug Administration, Silver Spring, Maryland, USA.; Food and Drug Administration, Silver Spring, Maryland, USA.; Food and Drug Administration, Silver Spring, Maryland, USA.; Food and Drug Administration, Silver Spring, Maryland, USA.; Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.
BT - Pharmacoepidemiology and drug safety
C5 - Financing & Sustainability; Healthcare Disparities; Opioids & Substance Use
CP - 11
CY - England
DO - 10.1002/pds.5312
IS - 11
JF - Pharmacoepidemiology and drug safety
LA - eng
M1 - Journal Article
PB - John Wiley & Sons Ltd
PP - England
PY - 2021
SN - 1099-1557; 1053-8569
SP - 1541
EP - 1550
EP - 
T1 - Prevalence of prescription opioid use during pregnancy in eight US health plans during 2001-2014
T2 - Pharmacoepidemiology and drug safety
TI - Prevalence of prescription opioid use during pregnancy in eight US health plans during 2001-2014
U1 - Financing & Sustainability; Healthcare Disparities; Opioids & Substance Use
U2 - 34169607
U3 - 10.1002/pds.5312
VL - 30
VO - 1099-1557; 1053-8569
Y1 - 2021
Y2 - Nov
ER -